Table 1 Clinical characteristics of AML patients treated with azacitidine according to the diversity of their pretreatment BM T cell repertoire based on the Shannon diversity index.
AML patients with top 25% most diverse repertoires at day 0 (n = 11) | other AML patients (n = 30) | Pa | |
|---|---|---|---|
age at diagnosis median (range) | 68.4 (60.8–80.9) | 69.4 (61.0–83.6) | 0.72 |
AML origin, n (%) | |||
de novo | 6 (54.5) | 18 (60.0) | 1 |
secondary | 5 (45.5) | 12 (40.0) | |
BM blasts at day 0, % median (range) | 28 (13–66) | 50 (0–90) | 0.02 |
BM blasts at day 15, % median (range) | 15 (6–72) | 30 (9–72) | 0.03 |
NPM1 mutation | |||
present | 1 (9.1) | 8 (26.7) | 0.40 |
absent | 10 (90.9) | 22 (73.3) | |
FLT3-ITD mutation | |||
present | 0 (0.0) | 7 (23.3) | 0.16 |
absent | 11 (100.0) | 23 (76.7) | |
normal karyotype | |||
present | 5 (45.5) | 14 (46.7) | 0.39 |
absent | 5 (45.5) | 16 (53.3) | |
unknown | 1 (9.1) | 0 (0.0) | |
complex karyotype | |||
present | 2 (18.2) | 4 (13.3) | 0.20 |
absent | 8 (72.7) | 26 (86.7) | |
unknown | 1 (9.1) | 0 (0.0) | |
allogeneic HSCT | |||
performed | 5 (45.5) | 12 (40.0) | 1 |
not performed | 6 (54.5) | 18 (60.0) | |
